Kraft Heinz Co vs Novavax Inc — how do they compare? Kraft Heinz Co trades at $25.99 (market cap $30.66B), while Novavax Inc trades at $7.94 (market cap $1.30B). The key difference: Kraft Heinz Co is far larger — about 23.6× Novavax Inc's market cap, and Kraft Heinz Co pays a 6.19% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| KHC | NVAX | |
|---|---|---|
Market Cap | $30.66B | $1.30B |
Sector | Consumer Staples | Health |
52-Week High | $28.94 | $11.19 |
52-Week Low | $21.21 | $6.22 |
Enterprise Value | $47.71B | $800.50M |
Dividend Yield | 6.19% | — |
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $26.05, up 0.66% today, with a bullish technical signal and recent earnings beats. The stock shows strong operating cash flow of $4.46B in 2025 but faces profitability challenges with a net income margin of -23.05%. Analysts are mixed, with 57% holding a neutral stance, while the company's reorganization aims to spur growth. The dividend yield remains attractive at approximately 6.4%, supported by solid cash generation.
Outlook: KHC offers value with a low P/B of 0.73 and high dividend, but risks include persistent net losses and high debt. The upcoming Q2 2026 earnings on August 5 will be critical for confirming turnaround progress. Investors should weigh the dividend stability against fundamental weaknesses in a competitive food sector.
Novavax (NVAX) trades at $7.86, down 4.26% on the day amid a bearish technical signal, though it has beaten earnings estimates for the last three quarters. The company reported $1.12 billion in revenue for 2025 with a net income of $440.30 million, yet faces negative shareholder equity and cash flow challenges. Recent news highlights stock volatility and shareholder dissent at the AGM, while analyst consensus remains largely bullish with a $14.00 price target.
The outlook for NVAX hinges on sustaining profitability and managing cash burn, with significant upside potential per analyst targets but substantial risks from negative equity, competitive pressures, and reliance on vaccine demand. Investors must weigh the high volatility and financial health concerns against the optimistic Wall Street ratings.
Trailing returns across standard periods
Latest headlines on both assets
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →